版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
東西方肝癌的分析比較本文檔共40頁;當(dāng)前第1頁;編輯于星期五\22點4分Asian(n=342)Non-Asian(n=1350)ProportionsurvivingTime(months)0.01.00.80.60.40.202468101214160246810121416GefitinibPlaceboImportanceofEthnicityforMTA
─thelessonsofISELtrial本文檔共40頁;當(dāng)前第2頁;編輯于星期五\22點4分EGFRmutationratesineachsubgroupStudyCentreNo.ofpatientsAdenoCa(+BAC)(%)M(%)F(%)Smokers(%)n-smokers(%)Taiwan1NTUH624925612956Taiwan2VGH-T3767.452724469Korea3SeoulNU90219331326Japan4NCCTokyo666153693568Japan5AichiCCH596444704271HK6ChineseU7232————China7PekUMCH7648.632.334.8——Italy8*UChieti37510630725Shihetal,IJC2005Chouetal,CCR2005Hanetal,JCO2005Takanoetal,JCO2005*onlyAdenoCaMitsudomietal,JCO2005Lungetal,PAACR2005Muetal,CCR2005Machettietal,JCO2005本文檔共40頁;當(dāng)前第3頁;編輯于星期五\22點4分LiverCancerintheWorld
FerlayJetal.IARCPress,2001.Men(396,364)/Women(165,972)NorthAmerica(%)2.07/2.61Central&SouthAmerica(%)2.09/4.33Africa(%)6.90/8.69Europe(%)8.21/10.45Asia(%)81.54/74.13Oceania(%)0.25/0.27本文檔共40頁;當(dāng)前第4頁;編輯于星期五\22點4分GeographicdifferencesintheresultsofclinicaltrialsforadvancedHCC本文檔共40頁;當(dāng)前第5頁;編輯于星期五\22點4分Sorafenib
Median:46.3weeks(10.7mo)
(95%CI:40.9,57.9)SurvivalProbabilityWeeksHazardratio(S/P):0.69(95%CI:0.55,0.88)
P=0.00058*Placebo
Median:34.4weeks(7.9mo)
(95%CI:29.4,39.4)1.0000.750.500.250808162432404856647202742412051611086738120Patientsatrisk
Sorafenib:027622417912678472572Placebo:299303PhaseIIISHARPTrial
Overallsurvival(Intention-to-treat)LlovetJetal,
NEnglJMed.2008Jul24;359(4):378-90
(7.9mo)本文檔共40頁;當(dāng)前第6頁;編輯于星期五\22點4分ComparisonofTx(-)ControlArmsP’tNoMedianOSPVTTNMStageIVOkudaStageIIIECOGIII/IVSpain10217M23.5%54.9%0%*0%*HK1063M60.0%90.6%14%13%*Spanishtrialsexcluded“End-stagedisease”LlovetJM,Hepatology1999;29:62-7YeungYP,AmJGastroenterol2005;100:1995-2004EASTVSWEST本文檔共40頁;當(dāng)前第7頁;編輯于星期五\22點4分Randomizedtrials-octreotidevsplacebo本文檔共40頁;當(dāng)前第8頁;編輯于星期五\22點4分StudySchemaofSHARPandAPStudiesSorafenib400mgbidPlaceboEligibilityAdvancedHCCECOG0-2Child-PughANopriorsystemictherapyStratificationMacroscopicvascularinvasion(portalvein)and/orextrahepaticspreadECOGPSGeographicareaRANDOMIZE本文檔共40頁;當(dāng)前第9頁;編輯于星期五\22點4分PhaseIIISHARPandAsia-PacificOverallSurvivalSorafenib
Median:10.7months
(95%CI:40.9,57.9)SurvivalProbabilityMonthsHazardratio(sor/pla):0.69
(95%CI:0.55,0.87)
P=0.00058*Placebo
Median:7.9months
(95%CI:29.4,39.4)1.0000.750.500.2502024681012141618SurvivalProbabilitySorafenib
Median:6.5months
(95%CI:5.6-7.6)Placebo
Median:4.2months
(95%CI:3.7-5.5)HR(S/P):0.68P=0.0140.250.500.751.0000Months248101214162022618LlovetJM,etal.NEnglJMed2008:359:378-90
ChengAL,etal.ASCO2008,Abstract4509.
SHARPAsia-Pacific本文檔共40頁;當(dāng)前第10頁;編輯于星期五\22點4分Asia-PacificLiverCancerStudyvsSHARP:
BaselinePatientCharacteristicsAsia-Pacific
(N=226)SHARP1
(N=602)Medianage(range),years51(23-86)67(21-89)Hepatitisvirusstatus(HBV/HCV),%73/818/28Sex(Male),%8587ECOGPS(0/1/2),%26/69/5 54/38/8Macroscopicvascularinvasion,%3538Extrahepaticspread,%6951BCLCStage(B/C),%4/9617/82No.oftumorsites,%111442353132012≥43513Sitesofdisease,% Lung5021 Lymphnode32261LlovetJ,etal.NEnglJMed2008:359:378-90
.本文檔共40頁;當(dāng)前第11頁;編輯于星期五\22點4分LlovetJMetal.Lancet.2003;362:1907-1917.EndStageAdvancedStageIntermediateStageEarlyStageSurgicalTreatmentsLocalAblationNewAgentsTACEHCC(30%)Potentiallycurativetreatments5-yrsurvival:50-70%(50-60%)Randomizedtrialsmediansurvivalifuntreated:6-16mo(10%)BSCsurvival<3moHCCtreatmentschedule(BCLC)本文檔共40頁;當(dāng)前第12頁;編輯于星期五\22點4分Meta-analysisofPhaseIIIclinicalTrialsofHCCDatabasesMedline,Cancerlit,CochraneDatabaseofSystematicReviews,CochraneCentralRegisterofControlledTrials,DatabaseofAbstractsofReviewsofEffect,andASCOProceedings,2005–2007Articles/abstractspublishedJan1996toJun2007TrialsregisteredatthathavecompletedpatientrecruitmentKeywords:‘Hepatocellularcarcinoma’OR‘livercancer’OR‘HCC’‘Randomizedcontrolledtrial’OR‘randomizedcontrolledstudy’InclusioncriteriaRandomizedcontrolledtrialsofsystemictherapyforHCCpatientswhowerenotresectableandnotsuitableforlocaltherapy(TACE,PEIT,etc.)Placebo/supportivecareasthecontrolarm本文檔共40頁;當(dāng)前第13頁;編輯于星期五\22點4分Meta-regression:Predictorsofsurvivalofthecontrolgrouppatients(1)VariablesNParameterestimateSETPvalueIntercept113.145960.7443024.2267250.003904ChildA%110.033530.0097333.4450430.010763HBV%110.050190.0167462.9970640.020025Asian11-5.704470.983315-5.801270.000663R2=0.6463.571.88monthsinAsiantrials
5.961.46monthsinnon-Asiantrials.P=0.02ThemeanSDofthemedianoverallsurvivaltimewas
本文檔共40頁;當(dāng)前第14頁;編輯于星期五\22點4分HCCPS0-2,ChildAorBPS>2orChildCPVT(-)PVT(+)Single2or3,3cm4,3cmICGgood*ICGbad*ResectionAblation,Transplan-tationTACEMainPV(-),extra-hepaticspread(-)MainPV(+)orextra-hepaticspread(+)TACEBSCNewagentsBSCBil.2mg/dlBil.2mg/dlBil.2mg/dlBil.2mg/dlEarlystage(singleor3nodules3cm,PS0)Intermediatestage(multi-nodular,PS0)Advancedstage(portalinvasion,N1,M1,PS1-2Terminalstage(PS>2,ChildC)NTUHpracticeBCLCguidelineResectionAblation,Transplan-tationTACENewagentsBSCSingle,PH(-)Multiple,PH(+)本文檔共40頁;當(dāng)前第15頁;編輯于星期五\22點4分MakuuchiM.etal,HepatologyResearch2007JapanGuidelineEmbolizationhepaticarterialinfusionchemotherapy本文檔共40頁;當(dāng)前第16頁;編輯于星期五\22點4分GeographicdifferencesintheetiologyofHCCimplicationinthedevelopmentofMTAs本文檔共40頁;當(dāng)前第17頁;編輯于星期五\22點4分EtiologyofHCC
—DistinctGeographicDistribution
RiskFactorsHepatitisBvirusHepatitisCvirusAlcoholTobaccoOralcontraceptivesAflatoxinOtherandemergingriskfactors/cofactors
EstimateRange22 4~-5860 12~72458~5712 0~14---10~50
Limitedexposure<5---
EstimateRange20 18~-4463 48~942015~3340 9~51
--- ---
Limitedexposure--- ---
EstimateRange60 40~9020 9~56---11~4122 ---8---
Importantexposure<5 ---BoschFXetal.Gastroenterology2004;127:S5-16.EuropeandUnitedStates(%)Japan(%)AsiaandAfrica(%)本文檔共40頁;當(dāng)前第18頁;編輯于星期五\22點4分IsHBV-relatedHCCamoreaggressivetumor?IsHBV-relatedHCCassociatedwithmolecularchangeswhichaffectmoleculartherapy?HBV-relatedHCC本文檔共40頁;當(dāng)前第19頁;編輯于星期五\22點4分HCC─EastvsWestLong-termresultsaftersurgicaltreatmentweresimilarinWestandEastwhenclinicopatnologicfactorswereaccountedfor.PawlikTMetalLiverTransplantation2004;10(suppl1)74-80TaeckDetalLiverTransplantation2004;10(suppl1)58-63
本文檔共40頁;當(dāng)前第20頁;編輯于星期五\22點4分HBVvs.HCVHCC
ItalianLiverCancergroupSurvivalinpatientswithadvancedHCC.HBV-HCCpatientshadalowersurvivalthanHCV-HCCpatients(p=0.025)PatientswithHBV-HCCtendedtohavepoorprognosis;~CantariniMCetal:AmJGastroenterol2006;101:91-8.
andthedifferencebecamestatisticallysignificantamongpatientswithadvancedHCC本文檔共40頁;當(dāng)前第21頁;編輯于星期五\22點4分HBVvs.HCVHCCinNTUH
Survivalforpatientswithadvancedds.927patientsreceivingsupportivecareorchemotherapy.EtiologyMedian survival(M)1year(%)3year(%)5year(%)10year(%)HBV2.512.43.40.80.5HCV3.421.78.52.21.1B+C3.410.83.11.50NBNC2.611.23.11.01.0HCV+HCV-HCCpatientshadbettersurvivalthanHBV-HCCpatientsChenCHetal.
EurJCancer.2006Oct;42(15):2524-9.Epub2006Aug22本文檔共40頁;當(dāng)前第22頁;編輯于星期五\22點4分IsHBV-relatedHCCamoreaggressivetumor?IsHBV-relatedHCCassociatedwithmolecularchangesthatwillaffectmoleculartherapy?HBV-relatedHCC本文檔共40頁;當(dāng)前第23頁;編輯于星期五\22點4分HBV-vs.HCV-associatedHCC
—GenomicsandProteomicsIizukaNetal.CancerRes2002;62:3939-44.KimWetal.ClinCancerRes2003;9:5493-500.HBVandHCVcausehepatocarcinogenesisbydifferentmechanisms.TheexpressionpatternofproteomeinHCCtissuesiscloselyassociatedwithetiologicfactors本文檔共40頁;當(dāng)前第24頁;編輯于星期五\22點4分ViralProteinsAndSignalTransductionPathwaysHCVcoreHCVcoreByHsuC,ShenYC,ChengAL本文檔共40頁;當(dāng)前第25頁;編輯于星期五\22點4分TranscriptomeclassificationofHCC~BoyaultSetal:Hepatol2007;45:42.basedon120surgicallyresectedHCC,includingtranscriptomeanalysison57HCCsand3adenomas,andqRT-PCRvalidationinadditional63HCCs26本文檔共40頁;當(dāng)前第26頁;編輯于星期五\22點4分MolecularEpidemiologyofHBV
—notallHBVsarethesameGenotypeCisassociatedwithanincreasedriskofHCCinTaiwan.(OR=5.11)
YuMWetal.JNatlCancerInst2005;97:265-72.GenotypeAHBVhasagreaterhepatocarcinogenicpotentialinsub-saharanAfricans.
KewMCetal.JMedVirol2005;75:513-21.GenotypeBisassociatedwithlessdecompensatedlivercirrhosisthangenotypeA,C,orDinUSA.
ChuCJetal.Gastroenterology2003;125:444-51.本文檔共40頁;當(dāng)前第27頁;編輯于星期五\22點4分SorafenibphaseIIHCCstudy
HCV-vs.HBV-relatedHCCP’tNo.MedianageRace(%) CaucasiansClinicalbenefit(%)PFS(median,M)TTP(median,M)OS(median,M)HCV+337182756.56.512.4HBV+136654533.547.3~Huitzil-MelendezFDetal:ASCO-2007GISymposiumAbstract#173.AretrospectiveanalysisP
.27.05.29本文檔共40頁;當(dāng)前第28頁;編輯于星期五\22點4分Sub-groupanalysisoftheSHARPtrialHCV1Alcohol2PS3MVI/EHS4(178)(159)0(325)1-2(277)-(421)+(181)OSSorafenib14.010.313.38.914.58.9(m)Placebo7.98.08.85.610.26.7HR0.58(0.37-0.91)0.76(0.50-1.16)0.68(0.50-0.95)0.71(0.52-0.96)0.52(0.35-0.85)0.77(0.60-0.99)TTPSorafenib7.65.55.55.39.64.1(m)Placebo2.83.92.92.84.32.7HR0.44(0.25-0.76)0.64(0.40-1.03)0.55(0.40-0.77)0.61(0.42-0.88)0.40(0.23-0.70)0.64(0.48-0.84)1.BolondiL,etal.Abstract129.PosterandoralpresentationatASCO-GI;Orlando,FL;January2008.
2.CraxiA,etal.Posterpresentation.Chicago.USA3.RaoulJ,etal.JClinOncol.2008;25:abstract4587.4.ShermanM,etal.JClinOncol.2008;25:abstract4584.本文檔共40頁;當(dāng)前第29頁;編輯于星期五\22點4分ThalidomidephaseIIHCCstudy
HCV-vs.HBV-relatedHCCP’tNo.MedianageObjectiveresponse+ AFPresponse(%)TTP(median)OS(median)HCV+3367.527.314.1W32.6WHBV+6153.613.18.3W21.4W~HsuCetal:Proc.ASCO2004:Abs#4198.P61<.001.09.03.08本文檔共40頁;當(dāng)前第30頁;編輯于星期五\22點4分GeographicfactorsshouldbetakenintoconsiderationintheinterpretationanddesignofclinicaltrialsofadvancedHCC.本文檔共40頁;當(dāng)前第31頁;編輯于星期五\22點4分PhaseIIstudyofbevacizumab+capecitabineinpatientswithadvanced/metastatichepatocellularcarcinomaHsuC-H1,YangT-S2,HsuC1,TohHC3,EpsteinR4,
HsiaoL-T5,LinZ-Z1,ChengA-L1
(ProcAmSocClinOncol2008:26;#4603)本文檔共40頁;當(dāng)前第32頁;編輯于星期五\22點4分MedianOS:5.9M(95%CI:4.1-9.7)MedianPFS:2.7M(95%CI:1.5-4.1)Bevacizumabpluscapecitabine
foradvancedHCCOSMedian:5.9M(95%CI:4.1-9.7)PFSMedian:2.7M(95%CI:1.5-4.1)~HsuCHetal:ProcASCO2008:Abstract#4603.
本文檔共40頁;當(dāng)前第33頁;編輯于星期五\22點4分Worldwide,multicenter,open-label, 1,200ptswithadvancedHCCStratifyGeographicRegionPriorTACETumorInvasionRandomize1:1Sunitinib37.5mg,qdaslongasclinicalbenefitSorafenib400mg,bidaslongasclinicalbenefitSTUDYA6181170
AMULTI-NATIONAL,RANDOMIZED,OPEN-LABEL,PHASEIIISTUDYOFSUNITINIBVERSUSSORAFENIBINPATIENTSWITHADVANCEDHEPATOCELLULARCARCINOMA本文檔共40頁;當(dāng)前第34頁;編輯于星期五\22點4分ConclusionSignificantgeographicdifferencesinclinicalpracticeandetiologyareobservedinHCC.Thesedifferencessignificantl
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 地理教學(xué)設(shè)計城市化過程與規(guī)劃
- 【核心素養(yǎng)目標(biāo)】人教版四下第六單元第一課時《漁夫和金魚的故事》教案
- 水利工程總包合同三篇
- 廣元市重點中學(xué)2022年物理高一下期末統(tǒng)考試題含解析
- 廣東執(zhí)信中學(xué)2021-2022學(xué)年物理高一第二學(xué)期期末質(zhì)量跟蹤監(jiān)視試題含解析
- 綠色物流:智能倉儲管理優(yōu)化策略
- 山東省濰坊高新技術(shù)產(chǎn)業(yè)開發(fā)區(qū)實驗學(xué)校2024年數(shù)學(xué)四年級第一學(xué)期期末考試試題含解析
- 山東省濰坊市高新區(qū)實驗學(xué)校2024-2025學(xué)年數(shù)學(xué)六上期末調(diào)研模擬試題含解析
- 山東省煙臺市龍口市2024年四年級數(shù)學(xué)第一學(xué)期期末教學(xué)質(zhì)量檢測試題含解析
- 甘肅省定西市2022年物理高一下期末質(zhì)量跟蹤監(jiān)視試題含解析
- 部編版(2024)道德與法治一年級上冊第12課《玩也有學(xué)問》教學(xué)課件
- 中班科學(xué)課件《有趣的不倒翁》
- 第14課 當(dāng)代中國的外交 課件高中歷史統(tǒng)編版2019選擇性必修1 國家制度與社會治理
- 2024版開業(yè)慶典活動策劃合同書5則范文
- 2024中國移動春季校園招聘高頻考題難、易錯點模擬試題(共500題)附帶答案詳解
- 職業(yè)生涯規(guī)劃與職場能力提升智慧樹知到答案2024年同濟大學(xué)
- 人教版地理八年級上冊第三節(jié)《民族》教學(xué)設(shè)計3
- 人教版地理七年級上冊第四章第二節(jié)《世界的語言和宗教》教學(xué)設(shè)計
- 個體商戶分紅合同范本
- 工地受傷賠償協(xié)議書
- 演講比賽評分表評委打分成績表
評論
0/150
提交評論